ライフサイエンスコーパス: breast cancer patient

1 nd correlate with metastatic status in human breast cancer patients.

2 erived from estrogen receptor-positive (ER+) breast cancer patients.

3 M2-7 genes correlated with poor prognosis in breast cancer patients.

4 ore the S100-targeting reagents for treating breast cancer patients.

5 d estimation of overall metastatic burden in breast cancer patients.

6 er chemotherapeutics, in several subtypes of breast cancer patients.

7 sidual cancer cells from neoadjuvant-treated breast cancer patients.

8 /CT was accurate in diagnosing recurrence in breast cancer patients.

9 pression is associated with poor survival in breast cancer patients.

10 prognostic marker and therapeutic target in breast cancer patients.

11 h high expression predicts poor prognosis in breast cancer patients.

12 as able to quantify the target analytes from breast cancer patients.

13 inked glycopeptides cell lines acquired from breast cancer patients.

14 ary tumor surgery on mortality in metastatic breast cancer patients.

15 monstrate the feasibility of our approach in breast cancer patients.

16 sion and longer progression-free survival of breast cancer patients.

17 as inversely correlated with ErbB2 levels in breast cancer patients.

18 s located within a minor allele expressed by breast cancer patients.

19 direct correlation with overall survival of breast cancer patients.

20 levels have been linked to poor prognosis in breast cancer patients.

21 rrelates with decreased survival of lung and breast cancer patients.

22 ingle cells isolated from six non-metastatic breast cancer patients.

23 tastasis-free survival and poor prognosis in breast cancer patients.

24 n, an effective neoadjuvant chemotherapy for breast cancer patients.

25 predict benefit from endocrine therapies for breast cancer patients.

26 gnificantly correlated with poor survival in breast cancer patients.

27 ategy to improve recurrence-free survival of breast cancer patients.

28 at could provide meaningful benefit to ER(+) breast cancer patients.

29 78 inversely correlated with HSPA5 levels in breast cancer patients.

30 endometrial cancer only in tamoxifen-treated breast cancer patients.

31 ors have yielded little clinical benefit for breast cancer patients.

32 evidence should be discussed with metastatic breast cancer patients.

33 eases risk of cancer recurrence and death in breast cancer patients.

34 atively correlated with FBXO11 expression in breast cancer patients.

35 isease-free survival in antiestrogen-treated breast cancer patients.

36 implications for anti-angiogenic therapy in breast cancer patients.

37 lliative primary tumor surgery in metastatic breast cancer patients.

38 stasis and an indicator of poor prognosis in breast cancer patients.

39 enes were associated with poorer outcomes in breast cancer patients.

40 survival of estrogen receptor (ER)-positive breast cancer patients.

41 lated with brain metastasis-free survival of breast cancer patients.

42 ssed, correlating with decreased survival in breast cancer patients.

43 ew imaging and therapeutic opportunities for breast cancer patients.

44 with mutant p53 status and poor prognosis in breast cancer patients.

45 r postoperative overall survival of lung and breast cancer patients.

46 in TLR5-responsive/unresponsive ovarian and breast cancer patients.

47 ting the TGF-beta signaling pathway in human breast cancer patients.

48 ctive trial enrolled clinical T0-4, N1-2, M0 breast cancer patients.

49 tched on in endocrine-resistant tumours from breast cancer patients.

50 ed TNM stage and poor clinical prognosis for breast cancer patients.

51 ignatures for guiding treatment decisions in breast cancer patients.

52 stasis is an important cause of mortality in breast cancer patients.

53 ecurrence are major barriers to survival for breast cancer patients.

54 y regimen is still an unmet medical need for breast cancer patients.

55 h a higher risk of distant metastasis in ER+ breast cancer patients.

56 lp eradicate this deadly feature in advanced breast cancer patients.

57 Metastasis is the primary cause of death in breast cancer patients.

58 cose uptake and metabolic gene expression in breast cancer patients.

59 ber of CTCs isolated from blood samples from breast cancer patients.

60 y were planned in 56% of prostate and 43% of breast cancer patients.

61 biomarker of poor outcome in ER(+) luminal A breast cancer patients.

62 sion and shorter metastasis-free survival in breast cancer patients.

63 astasis is associated with poor prognosis in breast cancer patients.

64 ator of DICER expression in large cohorts of breast cancer patients.

65 Nanog expression and poor prognosis of human breast cancer patients.

66 th anti-estrogen therapies in ER(+) stage IV breast cancer patients.

67 or (ER) is a target for endocrine therapy in breast cancer patients.

68 correlation with poor prognosis than HER2 in breast cancer patients.

69 astasis is the predominant cause of death in breast cancer patients.

70 d with poor distant relapse-free survival in breast cancer patients.

71 prognostic predictor of shorter survival of breast cancer patients.

72 elevated in metastatic lung lesions in human breast cancer patients.

73 (18)F-FDG PET/CT for only clinical stage III breast cancer patients.

74 related with metastatic progression in human breast cancer patients.

75 is significantly associated with outcome of breast cancer patients.

76 correlates with poor outcome for ER(-)/PR(-)breast cancer patients.

77 PALB2 WD40 domain that have been reported in breast cancer patients.

78 ned PTPN12 levels in tumors from a cohort of breast cancer patients.

79 1 expression correlates with the survival of breast cancer patients.

80 even independent data sets with totally 1079 breast cancer patients.

81 ls, and correlates with poor prognosis among breast cancer patients.

82 usting for known prognostic factors in young breast cancer patients.

83 predictive biomarker for clinical outcome of breast cancer patients.

84 tic targets for reducing tumor recurrence in breast cancer patients.

85 static niche formation and poor prognosis in breast cancer patients.

86 both correlate with poor clinical outcome in breast cancer patients.

87 nts and predicts a poor clinical outcome for breast cancer patients.

88 d in cancers and signifies poor prognosis of breast cancer patients.

89 ely used for many years for the treatment of breast cancer patients.

90 nhibitors (PARPi) benefit only a fraction of breast cancer patients.

91 method (81%) on 5,338 TMA images from 1,853 breast cancer patients.

92 independent prognostic factor for metastatic breast cancer patients.

93 the University of Pittsburgh Medical Center breast cancer patients.

94 3 paired primary and metastatic tissues from breast cancer patients.

95 r the testing of HER2 in clinical samples of breast cancer patients.

96 -suppressed gene signature that can stratify breast cancer patients.

97 were associated with better prognosis in all breast cancer patients.

98 status correlates well with poor survival of breast cancer patients.

99 nt decrease in overall survival in colon and breast cancer patients.

100 roestradiol ((18)F-FES) in ER-positive (ER+) breast cancer patients.

101 Bone metastasis is a major health threat to breast cancer patients.

102 es to maximize the benefits of radiation for breast cancer patients.

103 is associated with a poor prognosis in TNBC breast cancer patients.

104 is hemizygously or homozygously lost in some breast cancer patients.

105 tween Src kinases, paxillin, and survival of breast cancer patients.

106 h stem cell maintenance and poor survival of breast cancer patients.

107 within the clinical triple-negative group of breast cancer patients.

108 to neoadjuvant anti-HER2 therapy in HER2(+) breast cancer patients.

109 tly associated with poor overall survival of breast-cancer patients.

110 Data on 746 recently diagnosed breast cancer patients (300 non-Hispanic white, 303 non-

111 21 DNA repair genes were genotyped in 3,166 breast cancer patients, 569 ovarian cancer patients, and

112 Concerns exist regarding breast cancer patients' access to breast reconstruction,

113 We successfully apply iPANDA for stratifying breast cancer patients according to their sensitivity to

114 concentration) and in samples obtained from breast cancer patients after treatment with the drug for

115 that soy food consumption may be harmful to breast cancer patients, an analysis in 9514 breast cance

116 usetts, and New Hampshire (n=15,648 invasive breast cancer patients and 17,602 controls aged 40-79 ye

117 mor and normal breast tissue samples from 18 breast cancer patients and 18 healthy controls and const

118 the expression of HMGB2 in a cohort of 1068 breast cancer patients and found an association with inc

119 5 (HSPA5) is a marker for poor prognosis in breast cancer patients and has an important role in canc

120 s has been correlated with poor prognosis in breast cancer patients and has been linked to tumor cell

121 e in peripheral blood T cells is impaired in breast cancer patients and is associated with blunted Th

122 n analyzed gene expression profiles of human breast cancer patients and patient-derived xenograft (PD

123 also correlates with a high IGFBP3 status in breast cancer patients and predicts a poor clinical outc

124 normal appearing breast tissue obtained from breast cancer patients and tumor-bearing rats.

125 stimated from dynamic (18)F-FDG PET scans of breast cancer patients and used to simulate time-activit

126 ved downregulation of gp130 and IL6Ralpha in breast cancer patients and was independent of plasma IL6

127 9 polymorphisms and response to tamoxifen in breast cancer patients and, consequently, CYP2C19 genoty

128 selectively enriched in the tumor stroma of breast cancer patients, and depletion of these factors f

129 (mitochondrial DNA) reduction, often seen in breast cancer patients, and EMT is unknown.

130 at aligned collagen predicts poor outcome in breast cancer patients, and postulate this is because it

131 reliable prognostic biomarker in ER positive breast cancer patients, and predictive of preclinical se

132 cacy of docetaxel and thiotepa on metastatic breast cancer patients; and metastatic sites also affect

133 Hispanic and non-Hispanic black breast cancer patients are more likely than non-Hispanic

134 ofiling data in a retrospective study of 510 breast cancer patients as a test set and 516 breast canc

135 breast cancer patients as a test set and 516 breast cancer patients as an independent validation set.

136 -positive disease and stratify ESR1-positive breast cancer patients as responders to endocrine therap

137 ing therapeutic inhibitors of MYC with basal breast cancer patients as this could lead to increased m

138 hed tumor and adjacent normal tissue from 50 breast cancer patients as well as 23 normal breast tissu

139 hat correlates with poor overall survival in breast cancer patients as well as melanoma patients part

140 -medical out-of-pockent expenses incurred by breast cancer patients at HUM were US$233 (95% CI 170-30

141 rmine whether survival differed for invasive breast cancer patients based on hormone receptor (HR) st

142 itors to reduce recurrence and metastasis in breast cancer patients based on its ability to induce tu

143 In tumor tissue from breast cancer patients, beta3 was significantly elevated

144 In breast cancer patients, both abundance of CTC clusters a

145 enopausal estrogen receptor-positive (ER(+)) breast cancer patients, but resistance remains a major c

146 standard-of-care for newly diagnosed HER2(+) breast cancer patients, but some patients treated with t

147 s is one of the chief causes of mortality in breast cancer patients, but the mechanisms that drive th

148 gen receptor (ER) antagonist administered to breast cancer patients by monthly intramuscular injectio

149 il domain could be of therapeutic benefit to breast cancer patients by restoring Nrdp1 protein.

150 antly associated with poorer survival in the breast cancer patient cohort (n = 1441).

151 se associations were validated in a familial breast cancer patient cohort.

152 g vimentin and TF in the blood of metastatic breast cancer patients consistent with our observations.

153 growth; low expression levels of ZMYND11 in breast cancer patients correlate with worse prognosis.

154 ent of personalized treatment strategies for breast cancer patients could be improved by considering

155 the mTOR/S6K pathway; evaluation of multiple breast cancer patient data sets revealed that high DAPK1

156 Analysis of TCGA breast cancer patient data showed significant correlatio

157 ases, the leading cause of death in advanced breast cancer patients, depend on tumor cell interaction

158 We have created a large collection of breast cancer patient-derived tumor xenografts (PDTXs),

159 mics to profile protein expression across 24 breast cancer patient-derived xenograft (PDX) models.

160 finally identified 4932 eligible metastatic breast cancer patients diagnosed between 2010-2013, incl

161 ts with other breast tumor subtypes or older breast cancer patients did not seem to benefit effects o

162 Of interest, bioinformatic analysis of 1971 breast cancer patients disclosed a significant correlati

163 asatinib, to mitigate HOXA1 up-regulation in breast cancer patients displaying tamoxifen resistance.

164 ay significantly increase response rates for breast cancer patients, especially those with HER2 and E

165 , we showed that brain metastases from human breast cancer patients expressed higher levels of FBP an

166 ystemic staging of newly diagnosed stage III breast cancer patients, factors in addition to stage may

167 Furthermore, in human breast cancer patients, FBXW7 expression in peripheral b

168 rerequisite for identifying methods to treat breast cancer patients featuring such mutations.

169 rmline DNA of 814 normal individuals and 850 breast cancer patients for deletion or duplication of UB

170 encing of constitutional genomic DNA from 24 breast cancer patients from 11 Finnish breast cancer fam

171 and tumor exomes and transcriptomes from 90 breast cancer patients from TCGA.

172 Additionally, we applied INTEGRATE to 62 breast cancer patients from The Cancer Genome Atlas (TCG

173 rapy response, in order to identify specific breast cancer patient groups suited for the application

174 TCs isolated from bone marrow specimens from breast cancer patients, Grp78-positive stress granules w

175 breast cancer patients (<40 y) than in older breast cancer patients (>/=40 y), ruling out the assumpt

176 d to improve the survival of triple-negative breast cancer patients; however, such therapy is challen

177 n unfavorable relapse-free survival (RFS) in breast cancer patients (HR = 1.93, 95%CI: 1.33-2.80, p =

178 ve treatments provide persistent benefits to breast cancer patients in low-estrogen situations and sh

179 dentified in 189 Northern Finnish hereditary breast cancer patients in parallel sequencing of 796 DDR

180 ved peptide vaccines administered to HER2(+) breast cancer patients in the adjuvant setting suggest s

181 cting local recurrence and survival in young breast cancer patients in the Prospective study of Outco

182 ssion of the nuclear receptor 4A1 (NR4A1) in breast cancer patients is a prognostic factor for decrea

183 djuvant systemic therapy in the treatment of breast cancer patients is increasing beyond the scope of

184 Treatment of stage IV metastatic breast cancer patients is limited to palliative options

185 that the elevation of circulating aPLs among breast cancer patients is specifically associated with i

186 A missense variant detected in breast cancer patients located in the NTD impairs HR sti

187 colonization, and metastasis in mice, and in breast cancer patients, loss of E6AP associates with poo

188 DMR was not significantly higher in younger breast cancer patients (<40 y) than in older breast canc

189 ab is the standard of care for HER2-positive breast cancer patients, markedly improving disease-free

190 e cells derived from a brain metastasis of a breast cancer patient (MDA-MB-361).

191 Breast cancer patient miR-424 levels positively associat

192 In breast cancer patients, more than 45 different PET trace

193 Breast cancer patients (n>1000) with high KSR1 showed be

194 Correlation of relapse-free survival of breast cancer patients (n=2878) with expression levels o

195 r 3 population-based case-control studies of breast cancer patients (n=4,608) diagnosed from 1994 to

196 evious cytotoxic regimens (four or fewer for breast cancer patients), not including adjuvant or neoad

197 We show here that breast cancer patients of the claudin-low subtype have s

198 ses occur in approximately 70% of metastatic breast cancer patients, often leading to skeletal injuri

199 n 40 y (<40 y group) with that in a group of breast cancer patients older than 40 y (>/=40 y group).

200 present in the bone marrow of non-metastatic breast cancer patients, only part of which are derived f

201 DNs for those associating with exosomes from breast cancer patients or controls.

202 observed that high serum resistin levels in breast cancer patients positively correlated with tumor

203 Clinically, breast cancer patients possess sCLU expression only in m

204 r a role of immune components in influencing breast cancer patients' prognosis.

205 n clinical trial samples from ER+ metastatic breast cancer patients randomized either to the SERD ful

206 strogen receptor (ESR1) determines whether a breast cancer patient receives endocrine therapy, but do

207 Lastly, we show that in HER2(+) breast cancer patients receiving adjuvant chemotherapy (

208 gical procedure performed, demonstrates that breast cancer patients receiving neoadjuvant chemotherap

209 dividual S100, especially the mRNA level, in breast cancer patients remain elusive.

210 t define endocrine response in ESR1-positive breast cancer patients remain poorly understood.

211 action with obesity and physical activity in breast cancer patients remains unclear.

212 ease-free and overall survival of ERalpha(+) breast cancer patients resistant to conventional endocri

213 -analysis of microarray data from over 4,000 breast cancer patients revealed that elevated Notch path

214 High DDX3 expression was present in 35% of breast cancer patient samples and correlated with marker

215 Importantly, this mechanism is manifested in breast cancer patient samples and TCGA database, which s

216 Consistently, breast cancer patient samples portrayed a strong and sig

217 analysis of the gene expression profiles of breast cancer patient samples revealed that co-elevated

218 n nuclear FOXM1 and total NBS1 expression in breast cancer patient samples, further suggesting that N

219 In breast cancer patient samples, there is a high correlati

220 is significantly higher in high-grade human breast cancer patient samples, whereas depletion of PAK4

221 32 non-small cell lung cancer (NSCLC) and 22 breast cancer patient samples, yielding 60 to 100% of th

222 a tissue microarray with 149 non-metastatic breast cancer patient samples.

223 ations between FOXM1 and OTUB1 expression in breast cancer patient samples.

224 tions between FOXM1 and KIF20A expression in breast cancer patient samples.

225 able of specifically isolating exosomes from breast cancer patient samples.

226 from human oestrogen receptor (ER)-negative breast cancer patients showed a strong correlation betwe

227 This phase II study with ER+ breast cancer patients showed that (18)F-4FMFES PET achi

228 In breast cancer patients, significantly decreased let-7i l

229 reduced relapse-free and overall survival in breast cancer patients, suggesting that modulation of ER

230 We found that poor breast cancer patient survival was significantly associa

231 Metastasis is a critical event affecting breast cancer patient survival.

232 en right-sided gene expression and decreased breast cancer patient survival.

233 ways leads to markedly better predictions of breast cancer patients' survival in an independent cohor

234 dity was further supported by the finding in breast cancer patients that ABCA1 was overexpressed in 4

235 f these data, we conclude that HER2-positive breast cancer patients that have been treated with trast

236 o predict, after the first cycle of therapy, breast cancer patients that would eventually achieve a c

237 Firstly, we show that in breast cancer patients the pro-angiogenic activity of TE

238 To accommodate future needs of breast cancer patients, the companion diagnostic model w

239 Among breast cancer patients, those diagnosed with the triple-

240 In breast cancer patient tissues, elevated levels of DP103

241 monitor pathological response and outcome of breast cancer patients to chemotherapy early following t

242 n the use of WAT-derived progenitor cells in breast cancer patients to enhance the quality of breast

243 with favorable response of ERalpha-positive breast cancer patients to tamoxifen.

244 as a potential biomarker for the response of breast cancer patients to Vinca alkaloid drug treatment.

245 tes and CTRCD in a prospective cohort of 170 breast cancer patients treated with doxorubicin with or

246 of 102 postmenopausal, HR + HER2- metastatic breast cancer patients treated with everolimus-exemestan

247 ACOSOG Z1071 enrolled cT0-4N1-2 breast cancer patients treated with neoadjuvant chemothe

248 In node-positive breast cancer patients treated with neoadjuvant chemothe

249 Participants included 5569 early-stage breast cancer patients, treated with breast-conserving s

250 a, a clinical study conducted in a cohort of breast cancer patients uncovered that, in HER2+ patients

251 were collected at standardized intervals in breast cancer patients undergoing doxorubicin and trastu

252 In breast cancer patients undergoing doxorubicin therapy, e

253 s remain a potentially preventable event for breast cancer patients undergoing mastectomy.

254 e, we report that a high expression of AR in breast cancer patients was associated with shorter overa

255 low MCPIP1 expression in tumor samples from breast cancer patients was strongly associated with poor

256 In a cohort of 1,596 breast cancer patients, we analyzed the associations of

257 combination with bioinformatics analyses of breast cancer patients, we have identified a role for No

258 e hundred and forty-nine lymph nodes from 38 breast cancer patients were evaluated in this study.

259 Metastatic breast cancer patients were identified in the SEER regis

260 positively correlated in tissue samples from breast cancer patients, where high expression of both BC

261 els of STYX and FBXW7 are anti-correlated in breast cancer patients, which affects disease prognosis.

262 laboratory tests is powerful in identifying breast cancer patients who are at high risk of recurrenc

263 Breast cancer patients who bear loss-of-function alleles

264 he residual risk of recurrence was higher in breast cancer patients who had acquired chemoresistance.

265 h aromatase inhibitors can be considered for breast cancer patients who have T-scores less than -2.0.

266 used to identify estrogen receptor positive breast cancer patients who may benefit from therapy targ

267 er metastasis on the prognosis of metastatic breast cancer patients who received combined chemotherap

268 a collection of gene expression datasets on breast cancer patients who received neoadjuvant chemothe

269 Importantly, breast cancer patients who responded to letrozole expres

270 , representing novel therapeutic targets for breast cancer patients who smoke.

271 metastasis-free and relapse-free survival of breast cancer patients who underwent therapy.

272 R-155 may be useful in the identification of breast cancer patients who will benefit from an IR-based

273 PTX/CBP regimen neoadjuvant chemotherapy in breast cancer patients, who also tend to achieve patholo

274 Importantly, breast cancer patients whose tumors express both low str

275 utation in UBE2T was detected in a high-risk breast cancer patient with wild-type BRCA1/2.

276 standard for axillary lymph node staging in breast cancer patients with a clinically and radiologica

277 n as an attractive treatment alternative for breast cancer patients with both HER2-low and -high expr

278 ebrospinal fluid tumor cells, CSFTC) of nine breast cancer patients with brain metastases revealed dy

279 h BCBM.Characterization of CTCs derived from breast cancer patients with brain metastasis (BCBM) may

280 The median survival time of breast cancer patients with brain metastasis is less tha

281 rcinoma and squamous cell carcinoma, and 306 breast cancer patients with clear clinical information.

282 nsitivity, as exemplified by triple-negative breast cancer patients with diminished SWI/SNF core memb

283 otential to lead to personalized therapy for breast cancer patients with early-stage high-risk diseas

284 for exploring the possibility that sporadic breast cancer patients with EMSY amplification might ben

285 Furthermore, in breast cancer patients with ER-positive primary tumors w

286 ertuzumab) prolong survival in HER2-positive breast cancer patients with extracranial metastases.

287 Notably, NR4A1 expression is elevated in breast cancer patients with high immune infiltration and

288 LumA, and LumB breast cancer subtypes of 512 breast cancer patients with invasive ductal carcinoma (I

289 Here, we report that breast cancer patients with low MFN2 expression are asso

290 bsAbs as a promising therapeutic option for breast cancer patients with low or heterogeneous Her2 ex

291 The gene expression profile of luminal-type breast cancer patients with low RB expression revealed h

292 We recommend SPECT/CT in all breast cancer patients with no SN visualized on PI, all

293 peutics may be effective in the treatment of breast cancer patients with PIK3R1 loss.

294 rowth factor receptor 2-negative (ER+/HER2-) breast cancer patients with poor clinical outcome.

295 erative signalling cascade is upregulated in breast cancer patients with shorter survival and can be

296 associated with metastasis-free survival in breast cancer patients, with integrin beta3-binding prot

297 ediately using Hsp90 to improve outcomes for breast cancer patients without affecting traditional car

298 ast cancer survivors and whether it benefits breast cancer patients without diabetes.

299 n obesity-related cytokine-is upregulated in breast cancer patients, yet its impact on breast cancer

300 R) on initial (18)F-FDG PET/CT in a group of breast cancer patients younger than 40 y (<40 y group) w